Nuvation Bio is trading 4.7% up today at $6.55 following the release of positive updated Phase 2 data for its brain tumor drug, safusidenib.
- The company reported a 51.9% confirmed response rate and 79.1% 36‑month progression‑free survival in patients with IDH1‑mutant glioma.
- Management also announced an expansion of the clinical program, which is supporting bullish sentiment despite broader weakness in the biotech sector.